Milestone Pharmaceuticals Inc.
MIST · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | 0.07 | -0.01 | -0.07 |
| FCF Yield | -7.40% | -9.77% | -26.32% | -4.68% |
| EV / EBITDA | -13.02 | -11.90 | -3.21 | -16.11 |
| Quality | ||||
| ROIC | -15.22% | -32.42% | -41.49% | -18.17% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.82 | 0.97 | 0.67 | 0.55 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 21.94% | 9.89% | -103.32% | 2.24% |
| Safety | ||||
| Net Debt / EBITDA | -0.96 | -1.16 | -0.53 | -2.69 |
| Interest Coverage | -12.31 | -13.18 | -21.95 | -13.51 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -11,459.26 | 0.00 | 0.00 | -306.67 |